United States · 
What does Redmile Group invest in?
Redmile Group invests most often at Series B and Series C (68% of the rounds on record), in sectors such as Healthtech, Mental Health and Longevity.
Redmile Group highlights
- 01
24 cheques in the last 12 months
- 02
Mostly Series B and Series C: 68% of its rounds
- 03
Sole investor in 2 rounds, median $90M
- 04
3 exits from the portfolio
What they do
Filed 1 private fund offering with the SEC, the most recent in 2022-07From their own website
- Type
- VC firm (from a list, unverified)
- Cheque size
- Not stated
- Stages
- SeedSeries ASeries BGrowthPre-IPO
- Sectors
- HealthtechMental HealthLongevity
- Based in
- San Francisco, United States
- Cold pitches
- Not stated
The record
Every round we can evidence, newest first129 appearances
- 2026
18 rounds
- Sept
- Aug
- Jul
- Jul
- Jun
- Jun
- Jun
- Jun
- Jun
- Jun
- Jun
- May
- May
- Apr
- Mar
- Mar
- Mar
- Feb
- 2025
18 rounds
- Dec
- Dec
- Dec
- Nov
- Nov
- Nov
- Oct
- Oct
- Oct
- Sept
- Aug
- Aug
- Jul
- Jul
- May
- Apr
- Feb
- Feb
- 2024
7 rounds
- Nov
- Jul
- Jun
- Jun
An announcement gives the size of the round, not the size of this investor's cheque: the only rounds that imply a cheque are those where they were the sole named investor.
The team
Named by the firm itself, on a filing, its Form ADV or its company registration11 named
ANAmrit NagpalExecutive OfficeriFiling they signed
BRBryan Ranney CrapoChief Operating OfficeriForm ADV
GVGerard van Hamel PlaterinkManaging Director of General PartneriFiling they signed
JKJennifer Kate CiresiGeneral Counsel and Chief Compliance OfficeriForm ADV
JCJeremy Charles GreenManaging Member of the Managing Member of the General PartneriFiling they signed
JDJoshua Damian GarciaChief Financial OfficeriForm ADV
MSMichael Stewart LeeManaging DirectoriForm ADV
MLMike LeeMember of General PartneriFiling they signed
OJOwen John LearyManaging DirectoriForm ADV
RFRob FaulknerMember of General PartneriFiling they signed
RCRobert Carrington FaulknerManaging DirectoriForm ADV
We also hold 13 people at this firm from the lists this database was built from: a weaker source than the filings, since a list does not say when a title ended. Login to see them.
What the register says
From the firm's own filings with the SEC, which it must file accurately by law
$4.7Bassets it managesOct 2026
Registeredinvestment adviserfull reporting to the SEC
- Legal name
- Redmile Group, LLC
- SEC number
- CRD 143606
Funds on its Form ADV
18 private funds, $7.2B in gross assets · filed Jul 2024
Hedge 8Venture 7Private equity 3
- Redco II Master Fund, L.P.Hedge41 investors$1.5B
- Redmile Biopharma Investments III, L.P.Private equity330 investors$1.2B
- Redmile Capital Offshore II Master Fund, LTD.Hedge8 investors$962M
- Redmile Biopharma Investments II, L.P.Venture138 investors$828M
- Redmile Capital Offshore Master Fund, LTD.Hedge217 investors$729M
- Redmile Capital Fund, L.P.Hedge348 investors$654M
- Redmile Strategic LONG ONLY Trading SUB, LTD.Hedge47 investors$286M
- RAF, L.P.Venture2 investors$261M
- Redmile Strategic Trading SUB, LTD.Hedge115 investors$212M
- Redmile Growth Investments I, L.P.Venture3 investors$157M
And 8 more on the filing.
Exits from the portfolio
Companies it backed that were later bought or listed3 in all
SciodermBought by Amicus Therapeutics$847MAug 2015
Foundation MedicineBought by RocheUndisclosedJan 2015
Foundation MedicineListed$108MJul 2013
An exit counts when it came after the firm's first round in the company. From historical deal records.